S. Centanni (Milan, Italy), F. Chung (London, United Kingdom)
Efficacy and safety of transdermal tulobuterol (LABA) on asthma patients
J. T. Lin (Beijing, China)
|   |
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma
S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, L. Brookman (Horsham, United Kingdom; East Hanover, CA, United States Of America; Basel, Switzerland)
| |
The pharmacokinetic profiles of oral doxofylline and factors influencing the serum level
J. H. Lee, H. W. Namgung, S. Y. Kwon, H. I. Yoon, C. T. Lee (Seongnam-si, Gyeonggi-do, Republic Of Korea)
| |
Pharmacokinetics and lung bioavailability of Foster® using the standard actuator or a spacer
G. Poli, D. Acerbi, A. Rusca (Parma, Italy; Arzo, Switzerland)
| |
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
F. Mariotti, G. Poli, D. Acerbi, I. Burton, B. Elharrar (Parma, Italy; Wavre, Belgium; Paris, France)
| |
Corticosteroid lipophilicity is a more important determinant of corticosteroid uptake into human hepatocytes than serum protein binding
S. Janciauskiene, C. Orbjörn, P. Sjölin, S. Edsbäcker, A. Miller-Larsson (Malmö, Lund, Sweden)
| |
Exposure of human subcutaneous adipose tissue and skeletal muscle tissue to unbound active drug after inhalation of high-dose ciclesonide or budesonide
H. Boss, I. Steiner, A. Drollmann, R. Nave, M. Zeitlinger, C. Joukhadar (Konstanz, Germany; Vienna, Austria)
| |
Comparable efficacy of ciclesonide and fluticasone propionate and lower incidence of oropharyngeal candidiasis with ciclesonide in patients with well-controlled moderate to severe persistent asthma
R. Engelstätter, D. Dusser, H. McGoldrick, W. R. Pieters, M. Luengo, M. Hellwig (Paris, France; Downpatrick, United Kingdom; Helmond, Netherlands; Barcelona, Spain; Konstanz, Germany)
| |
Pronounced tissue and plasma protein binding of ciclesonide is responsible for reduced pharmacodynamic potency in the lung
G. Hochhaus, K. Wu, A. B. Blomgren, K. Ekholm, S. Edsbäcker (Gainesville, FL, United States Of America; Lund, Sweden)
| |
Inhaled mometasone benefits adult patients with asthma-like symptoms but not fulfilling functional asthma criteria
P. Rytilä, G. Lisa, S. Varghese, W. Chung, O. Selroos, T. Haahtela (Helsinki, Finland; Kenilworth, NJ, United States Of America)
| |
Effect of ascorbic acid on airway hyperresponsiveness in bronchial asthma
Y. S. Hwang, H. C. Kim, L. J. Jung, J. D. Lee (Jinju, Gyeongnam, Republic Of Korea)
| |
Effect of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) on small airways involvement in asthma: assessment using impulse oscillometry system (IOS)
M. Yamaguchi, A. Niimi, T. Ueda, M. Takemura, H. Matsuoka, M. Jinnai, K. Otsuka, T. Oguma, T. Takeda, H. Matsumoto, M. Mishima (Kyoto, Japan)
| |
Effect of β2-agonists on severe asthma exacerbation and asthma-related hospitalization
N. Lazareva, V. Arkhipov, A. Igonin, A. Tsoy (Moscow, Russian Federation)
| |
A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline
P. Ewing, S. Eirefelt, P. Andersson, A. Blomgren, A. Ryrfeldt, P. Gerde (Stockholm, Lund, Sweden)
| |
Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis
E. Bateman, H. Nelson, R. Beasley, J. Bousquet, S. Yancey, K. Kral, L. Sutton, P. Dorinsky (Wellington, New Zealand; Denver, CO, RTP, NC, United States Of America; Cape Town, South Africa; Montpellier, France)
| |
Inhibitory effects of budesonide and formoterol in combination on TGFβ-induced proteoglycan production by bronchial biopsy fibroblasts from healthy and mild asthmatic subjects
L. Todorova, L. Bjermer, A. Miller-Larsson, G. Westergren-Thorsson (Lund, Sweden)
| |
Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma
R. Aalbers, M. Mensing, M. Boorsma, R. E. Jonkers (Groningen, Zoetermeer, Amsterdam, Netherlands)
| |
Associations between genetic polymorphisms and withdrawals from controlled clinical trials in Caucasian and African American patients with asthma
P. Dorinsky, H. Ortega, S. Yancey, L. Edwards, A. Morris, L. Sutton, W. Anderson (Research Triangle Park, NC, United States Of America)
| |
Treatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils
R. Zeldin, M. Massanari, M. Blogg, P. Jimenez, G. Geba (East Hanover, NJ, United States Of America; Horsham, West Sussex, United Kingdom)
| |
Clinical effect of clean air administered directly to the breathing zone (airsonett airshower®) on perennial allergic asthma
C. Pedroletti, O. Zetterstrom, E. Millinger, K. Zara, K. Damm, B. Dahlén, P. Soderman (Stockholm, Linkoping, Huddinge, Sweden)
| |